北京时间1月31日,Tectonic Therapeutic公司盘中大涨10.90%,引起了市场广泛关注。
消息面上,富国银行(WFC)维持了对该公司的"增持"评级,并将目标价从79美元大幅上调至112美元,这表明分析师认为该公司未来有较大的上涨空间。
Tectonic Therapeutic是一家专注于发现和开发调节G蛋白偶联受体(GPCRs)活性的治疗性蛋白和抗体的生物技术公司。其GEODe技术平台旨在克服GPCRs靶向药物发现的现有挑战,以改变疾病的进程。富国银行看好该公司在这一细分领域的发展前景,因此上调了评级和目标价。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.